3 Positives From J&J's Latest Acquisition

Before you go, we thought you'd like these...
Before you go close icon

Johnson & Johnson completed its acquisition of privately held Aragon Pharmaceuticals earlier this week. Plans for the deal were first announced by J&J in June. Buyouts of smaller companies don't always work out that great, but the Aragon pickup should be good for J&J -- and its shareholders. Here are three positives that I see from this latest acquisition.

Source: Johnson & Johnson. 

1. Good fit 
J&J's Zytiga pulled in sales of $961 million in 2012. This year is looking to be even better, with sales for the prostate cancer drug totaling $739 million in just the first six months of 2013. That's the good news. The bad news is that J&J loses patent exclusivity for Zytiga in a little over three years from now.

Aragon's androgen receptor signaling inhibitor ARN-509, which is in phase 2 clinical trials, appears to be a good fit for J&J. Like Zytiga, ARN-509 targets prostate cancer. If eventually approved, the drug could potentially be marketed as a complementary treatment alongside Zytiga. J&J's sales team should be able to easily incorporate the second product into their strategy.

2. Good move to fend off rivals
With Zytiga going off-patent in 2016 and no potential replacement in late-stage studies, J&J has reason to worry about its prostate cancer franchise. Several other companies would love to capture market share from the big drugmaker.

Medivation is coming on strong with its prostate cancer drug Xtandi. The company, along with partner Astellas Pharma, racked up nearly $158 million in sales for Xtandi during the first half of this year. Like ARN-509, Xtandi is an adrogen receptor inhibitor.

Dendreon is also still plugging away with prostate cancer vaccine Provenge. While Provenge has been a big commercial disappointment since its approval in 2010, Dendreon is making efforts to position the vaccine as part of a regimen that includes rival drugs. The company has a clinical study under way with Provenge in combination with Zytiga and another study in process with Xtandi.

3. Good use of cash
As of the end of June, J&J reported total cash (including cash equivalents and short-term investments) of more than $25 billion. Putting that cash to good use seems like a smart move. I think the purchase of Aragon qualifies as a good use.

J&J paid $650 million up front for Aragon with up to $350 million more to possibly follow if specified milestones are reached. Basically, we're talking about paying at most $1 billion for a prostate cancer program that could realistically bring that much or more in every year if all goes well.

Investors are hoping they get to experience a bit of deja vu with the Aragon acquisition. J&J gained Zytiga with its buyout of Cougar Biotechnology in 2009. The price tag for that purchase? $1 billion. Zytiga made most of that cost back in its first year on the market.

Positively speaking
My view is that J&J's Aragon deal is clearly positive. Furthermore, my view of J&J itself remains very positive. The stock is up 25% so far in 2013. The company continues to deliver solid performance and make smart moves like the one with Aragon that position it well for the future. When you throw in the 3% dividend, J&J continues to look like a very good pick for long-term investors.

Johnson & Johnson appears to be investing its money wisely, but the important question is: What are you doing with yours? Millions of Americans have waited on the sidelines since the market meltdown in 2008 and 2009, too scared to invest and put their money at further risk. Yet those who've stayed out of the market have missed out on huge gains and put their financial futures in jeopardy. In our brand-new special report, "Your Essential Guide to Start Investing Today," The Motley Fool's personal finance experts show you why investing is so important and what you need to do to get started. Click here to get your copy today -- it's absolutely free.

The article 3 Positives From J&J's Latest Acquisition originally appeared on Fool.com.

Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

People are Reading